No Data
No Data
William Blair Maintains Beam Therapeutics(BEAM.US) With Buy Rating
Beam Therapeutics: Strong Clinical Progress and Growth Potential Justify Buy Rating
Beam Therapeutics Swings to Q4 Loss as Revenue Falls
Beam Therapeutics | 10-K: FY2024 Annual Report
Earnings Flash (BEAM) Beam Therapeutics Posts Q4 License and Collaboration Revenue $30.1M, Vs. FactSet Est of $17.2M
Beam Therapeutics | 8-K: Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
Unlock the Full List
sooogod : nbis.
GOGOY : Tem will be the next